Quanterix’s Simoa® technology drives advances in Alzheimer’s disease research presented at 2022 Clinical Trials On Alzheimer’s Disease (CTAD) conference

Close Up Scientist using microscope in laboratory room while making medical testing and research

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022.

China faces soaring Covid cases as hardline policy eases

Previous article

Dyson’s new air-purifying headphones come with a hefty price tag

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News